Case Study of MS Solutions in Action
Evaluating Cognitive Deterioration in MS Patients via Cogstate Digital Assessments
Cogstate supported safety assessment in a 24-month observational study of natalizumab in multiple sclerosis patients. 63 patients were treated and assessed prior to monthly infusions using a Cogstate battery and the Symbol Digit Modalities Test (SDMT). Using data from the Cogstate assessments, no patient showed evidence of sustained cognitive deterioration over the 24-month period. Data were relevant to ensuring long-term safety and sustained efficacy of treatment. (Gaudet D., et al., DOI: https://doi.org/10.1016/j.atherosclerosis.2021.06.789)